Leonardo Gomes da Fonseca

机构：Instituto do Câncer do Estado de São Paulo, D’Or Institute for Research and Education, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · ORCID：0000-0002-0216-3618

发表论文 157 篇 · 总被引 1847 次 · h-index 20

代表论文

• Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial (2025 · The Lancet · 被引 353)
• Cholangiocarcinoma 2026: status quo, unmet needs and priorities (2025 · Nature Reviews Gastroenterology & Hepatology · 被引 74)
• Disparities in access to systemic therapies for patients with hepatocellular carcinoma: an analysis from the International Liver Cancer Association (2025 · The Lancet Regional Health - Europe · 被引 9)
• Breaking Barriers for Intensive Care Admission in Patients With Advanced HCC on Immunotherapy (2025 · Liver International · 被引 8)
• 148O Overall evaluation of health-related quality of life (HRQoL) and efficacy assessment in patients (pts) who discontinued (d/c) due to treatment-related adverse events (TRAEs): Results from CheckMate 9DW (2025 · Annals of Oncology · 被引 6)
• “Hepatocellular carcinoma surveillance: Current challenges in Latin America” (2025 · Annals of Hepatology · 被引 6)